RemeGen Co., Ltd. (SHA:688331)

China flag China · Delayed Price · Currency is CNY
98.67
-0.33 (-0.33%)
At close: Feb 27, 2026
203.23%
Market Cap 49.28B
Revenue (ttm) 3.25B
Net Income (ttm) 708.52M
Shares Out n/a
EPS (ttm) 1.29
PE Ratio 69.55
Forward PE 85.80
Dividend n/a
Ex-Dividend Date n/a
Volume 3,028,901
Average Volume 5,326,316
Open 98.50
Previous Close 99.00
Day's Range 98.13 - 100.79
52-Week Range 29.50 - 118.88
Beta 0.74
RSI 48.32
Earnings Date Mar 28, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial gro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 3,070
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688331
Full Company Profile

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.54% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.84% less than in 2023.

Financial Statements

News

There is no news available yet.